In the phase II, single-arm NeoCombi study, patients with resectable BRAF-mutated stage IIIB-C melanoma received 12 weeks of neoadjuvant targeted therapy with Dabrafenib plus Trametinib followed by surgical resection and a further 40 weeks of adjuvant therapy to complete 1 year in total. The gene discussed is BRAF; the disease is melanoma.